NASDAQ:FLXN - Flexion Therapeutics Stock Price, Price Target & More

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

Flexion Therapeutics (NASDAQ:FLXN) released its quarterly earnings results on Tuesday, May, 8th. The specialty pharmaceutical company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.33) by $0.23. The specialty pharmaceutical company had revenue of $2.19 million for the quarter, compared to analyst estimates of $1.99 million. View Flexion Therapeutics' Earnings History.

8 brokers have issued 12 month price objectives for Flexion Therapeutics' shares. Their forecasts range from $36.00 to $570.00. On average, they anticipate Flexion Therapeutics' stock price to reach $106.3750 in the next twelve months. View Analyst Ratings for Flexion Therapeutics.

Some companies that are related to Flexion Therapeutics include Array Biopharma (ARRY), Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Horizon Pharma (HZNP), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), The Medicines (MDCO), Portola Pharmaceuticals (PTLA), Emergent Biosolutions (EBS), Evotec (EVTCY), OPKO Health (OPK), Intercept Pharmaceuticals (ICPT), Arena Pharmaceuticals (ARNA) and Clovis Oncology (CLVS).

Headlines about FLXN stock have trended positive this week, Accern reports. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Flexion Therapeutics earned a media sentiment score of 0.45 on Accern's scale. They also assigned media headlines about the specialty pharmaceutical company an impact score of 43.64 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Flexion Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.94%), Rubric Capital Management LP (5.38%), Wells Fargo & Company MN (4.46%), Millennium Management LLC (1.84%), Wasatch Advisors Inc. (1.68%) and Schroder Investment Management Group (1.36%). Company insiders that own Flexion Therapeutics stock include Frederick W Driscoll, Mark Stejbach, Michael D Clayman, Neil Bodick, Samuel D Colella and Yamo Deniz. View Institutional Ownership Trends for Flexion Therapeutics.

FLXN stock was sold by a variety of institutional investors in the last quarter, including Bamco Inc. NY, BlackRock Inc., Wasatch Advisors Inc., Wells Fargo & Company MN, JPMorgan Chase & Co., Gagnon Securities LLC, Allianz Asset Management GmbH and Allianz Asset Management GmbH. View Insider Buying and Selling for Flexion Therapeutics.

FLXN stock was purchased by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, Millennium Management LLC, UBS Group AG, California Public Employees Retirement System, Trexquant Investment LP, Wexford Capital LP, Cubist Systematic Strategies LLC and DekaBank Deutsche Girozentrale. Company insiders that have bought Flexion Therapeutics stock in the last two years include Mark Stejbach, Michael D Clayman, Neil Bodick, Samuel D Colella and Yamo Deniz. View Insider Buying and Selling for Flexion Therapeutics.

Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of FLXN stock can currently be purchased for approximately $26.49.

Flexion Therapeutics has a market capitalization of $997 million and generates $350,000.00 in revenue each year. The specialty pharmaceutical company earns $-137,480,000.00 in net income (profit) each year or ($4.16) on an earnings per share basis. Flexion Therapeutics employs 251 workers across the globe.

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]